Genetic Profiling of Liver Cancer in Patients Undergoing Liver Transplantation

Baylor Research Institute40 enrolled

Overview

The purpose of this study is to determine whether genetic markers unique to liver cancer are present and to assess usefulness as a diagnostic tool.

Hepatocellular carcinoma (HCC) is the most common form of liver cancer and a growing trend worldwide. Decision-making regarding treatment for patients is limited by the lack of clinically actionable biomarkers. This is pronounced in the case for determining and monitoring liver transplant recipients. In an effort to improve diagnosis, the use of circulating serum-based microRNA isoforms (isomiRs) can serve as non-invasive, screening biomarkers in HCC patients pre- and post-transplantation of the liver.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hepatocellular Carcinoma

Interventions

None - Standard of CareOTHER

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with the diagnosis of HCC who are on the wait list for liver transplantation * Patients with the diagnosis of HCC who have been admitted to hospital, scheduled to undergo liver transplantation within the following 24 hours. * Age Range: 18 to 75 years old Exclusion Criteria: * Patients with metastatic HCC and patients with the diagnosis of HCC who are not on the wait list for liver transplantation. * Patients older than 75 years old and younger than 18 years old. * Patients who are unable to consent. * Pregnant patients.

Locations (1)

Baylor University Medical Center

Dallas, Texas, United States

Outcomes

Primary Outcomes

Using next-generation sequencing methods to detect isomiRs across different HCC cohorts at all stages undergoing liver transplantation.

Time frame: One year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.